6-MAPBT

6-MAPBT
Clinical data
Other names	6-(2-(Methylamino)propyl)-1-benzothiophene; MY300; MY-300
Drug class	Monoamine releasing agent; Serotonin 5-HT1B receptor agonist; Entactogen
ATC code	None;
Identifiers
	IUPAC name 1-(1-benzothiophen-6-yl)-N-methylpropan-2-amine;
PubChem CID	166478938;
Chemical and physical data
Formula	C12H15NS
Molar mass	205.32 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CC1=CC2=C(C=C1)C=CS2)NC;
	InChI InChI=1S/C12H15NS/c1-9(13-2)7-10-3-4-11-5-6-14-12(11)8-10/h3-6,8-9,13H,7H2,1-2H3; Key:ZTCVZGKXXWDMJJ-UHFFFAOYSA-N;

6-MAPBT, also known as 6-(2-(methylamino)propyl)-1-benzothiophene, is a possible entactogen of the phenethylamine, amphetamine, and benzothiophene families related to MDMA.^[1]^[2]^[3]

Other names6-(2-(Methylamino)propyl)-1-benzothiophene; MY300; MY-300

Quick facts Clinical data, Other names ...

Close

It acts as a monoamine releasing agent and serotonin receptor modulator.^[3] The drug's EC₅₀Tooltip half-maximal effective concentration values for monoamine release are 57 nM for serotonin and 71 nM for dopamine.^[3] It is also a potent agonist of the serotonin 5-HT_1B receptor, with an EC₅₀ of 24 nM, and is a potent antagonist of the serotonin 5-HT_2B receptor, with an IC₅₀Tooltip half-maximal inhibitory concentration of 72 nM.^[3] Conversely, it is far weaker as an agonist of the serotonin 5-HT_2A receptor (EC₅₀ = 959 nM) and is inactive at the serotonin 5-HT_1A receptor.^[3] In addition to the preceding actions, the drug is a monoamine oxidase A (MAO-A) inhibitor, with an IC₅₀ of 945 nM.^[3]

It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents.^[3] However, benzothiophenes like 6-MAPBT, despite their induction of dopamine release, are said to lack hyperlocomotion or stimulant-like effects in rodents.^[2]^[4]

6-MAPBT has been studied and patented by Matthew J. Baggott at Tactogen.^[1]^[3] The drug has also been patented by Mydecine and given the developmental code name MY300.^[5]

See also